EXPERIMENTAL HEMATOLOGY

Scope & Guideline

Transforming Hematology with Groundbreaking Research

Introduction

Immerse yourself in the scholarly insights of EXPERIMENTAL HEMATOLOGY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0301-472x
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1973 to 2024
AbbreviationEXP HEMATOL / Exp. Hematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

EXPERIMENTAL HEMATOLOGY focuses on advancing the understanding of hematopoiesis, hematological malignancies, and related therapeutic interventions. The journal emphasizes innovative research methodologies and interdisciplinary approaches to address key challenges in the field.
  1. Hematopoiesis and Stem Cell Biology:
    The journal covers extensive research on the mechanisms of hematopoiesis, including the development, differentiation, and function of hematopoietic stem cells (HSCs), progenitor cells, and their niches.
  2. Hematological Malignancies:
    Research on the molecular and cellular basis of hematological cancers, including leukemias, lymphomas, and myeloproliferative neoplasms, is a core area of focus, particularly mechanisms of tumorigenesis and therapeutic resistance.
  3. Therapeutic Innovations:
    EXPERIMENTAL HEMATOLOGY publishes studies on novel therapeutic strategies, including gene therapy, immunotherapy, and targeted treatments for hematological diseases, highlighting translational research.
  4. Microenvironment and Niche Interactions:
    The journal emphasizes the role of the bone marrow microenvironment and other niches in regulating hematopoietic cell behavior, interactions between different cell types, and their impact on disease.
  5. Epigenetics and Transcriptional Regulation:
    Research exploring the epigenetic landscape and transcriptional control mechanisms governing hematopoietic development and malignancies is prominently featured, reflecting the journal's commitment to understanding gene regulation.
  6. Systemic and Local Regulation of Hematopoiesis:
    Studies addressing the systemic factors influencing hematopoiesis and the local signals from the microenvironment that modulate hematopoietic function are integral to the journal's scope.
EXPERIMENTAL HEMATOLOGY is currently witnessing several emerging themes that reflect the cutting-edge advancements in hematology research. These trends indicate a shift towards more innovative methodologies and interdisciplinary approaches.
  1. Single-Cell Technologies:
    An increasing number of studies are employing single-cell RNA sequencing and other single-cell technologies to elucidate the heterogeneity of hematopoietic stem and progenitor cells, providing insights into their function and regulation.
  2. Metabolic Regulation:
    Research focusing on the metabolic pathways that influence hematopoietic stem cell function and differentiation is gaining prominence, highlighting the interplay between metabolism and cell fate.
  3. Inflammation and Immune Interactions:
    The role of inflammation and immune responses in regulating hematopoiesis and hematological malignancies is an emerging theme, with studies investigating how these factors influence disease progression.
  4. Gene Editing and Genetic Models:
    There is a notable increase in studies utilizing advanced gene editing techniques (e.g., CRISPR/Cas9) to model hematological diseases and explore genetic factors contributing to malignancies.
  5. Epitranscriptomics:
    The exploration of RNA modifications (e.g., m6A methylation) and their impact on gene expression and hematopoietic function is an emerging area of interest, reflecting the evolving understanding of post-transcriptional regulation.
  6. Therapeutic Targeting of the Microenvironment:
    Research targeting the bone marrow microenvironment to enhance hematopoietic stem cell recovery and improve treatment outcomes in hematological malignancies is gaining traction, indicating a shift towards niche-focused therapies.

Declining or Waning

While EXPERIMENTAL HEMATOLOGY continues to thrive in many areas, certain themes appear to be waning or experiencing decreased publication frequency. This could reflect shifts in research focus or advances in understanding that render some topics less prominent.
  1. Traditional Animal Models:
    Research utilizing conventional animal models for hematopoiesis and leukemia studies is less frequently published, potentially due to the increasing adoption of advanced in vitro and humanized models.
  2. Basic Hematology without Translational Focus:
    Papers focusing solely on basic hematological research without clear translational implications are becoming less common, as the field increasingly emphasizes studies that bridge basic science with clinical application.
  3. Single-Agent Therapeutic Studies:
    The publication of studies focusing exclusively on single-agent therapies without exploring combination strategies or innovative approaches appears to be declining, reflecting a shift towards more complex treatment paradigms.
  4. Epidemiological Studies:
    There has been a noticeable decrease in the publication of epidemiological studies related to hematological disorders, possibly due to a growing emphasis on mechanistic and experimental research.

Similar Journals

FEBS Journal

Advancing the Frontiers of Biochemical Research
Publisher: WILEYISSN: 1742-464XFrequency: 24 issues/year

FEBS Journal is a prestigious, peer-reviewed publication dedicated to advancing the field of biochemistry, cell biology, and molecular biology. Published by WILEY in the United Kingdom, this journal boasts an impressive impact factor and ranks in the top quartile (Q1) across multiple relevant categories, including Biochemistry, Cell Biology, and Molecular Biology, reflecting its significant contribution to scientific research. With an ISSN of 1742-464X and an E-ISSN of 1742-4658, the FEBS Journal publishes original research and comprehensive reviews that push the boundaries of knowledge and innovation in the biosciences. As a vital resource for researchers, professionals, and students alike, the journal offers Open Access options, ensuring that cutting-edge discoveries are accessible to a broad audience. With a publication history converging from 2005 to the present and a robust emphasis on high-quality scholarly work, the FEBS Journal remains an essential platform for the dissemination of significant findings and advancements in the life sciences.

Cell Stem Cell

Transforming Knowledge into Innovation in Stem Cell Science
Publisher: CELL PRESSISSN: 1934-5909Frequency: 12 issues/year

Cell Stem Cell, published by CELL PRESS, is a premier journal at the forefront of cellular biology, genetics, and molecular medicine. With an esteemed impact factor and recognized as a Q1 journal in multiple categories including Cell Biology, Genetics, and Molecular Medicine, it offers researchers, professionals, and students rigorous, peer-reviewed articles that shape the future of stem cell research and regenerative medicine. Located in Cambridge, MA, this journal has become an invaluable resource since its inception in 2007 and is committed to disseminating groundbreaking findings that drive innovation and understanding in these critical fields. By consistently ranking within the top percentile of its categories in Scopus, Cell Stem Cell remains an essential platform for scholarly communication, fostering collaboration among leading scientists worldwide. Although the journal does not currently offer open access options, its comprehensive insights are pivotal for anyone engaged in the study of stem cells and their applications.

Life Science Alliance

Empowering Research, Elevating Knowledge.
Publisher: LIFE SCIENCE ALLIANCE LLCISSN: Frequency: 6 issues/year

Life Science Alliance, published by LIFE SCIENCE ALLIANCE LLC, is a premier open access journal that has been making significant contributions to the fields of Biochemistry, Genetics and Molecular Biology, Ecology, Health, Toxicology and Mutagenesis, and Plant Science since its inception in 2018. With an impressive ranking in Scopus, including Q1 quartile positions and high percentiles in relevant categories, this journal is a vital resource for researchers, professionals, and students alike who seek to advance knowledge and innovation in life sciences. The journal operates on an open access model, ensuring that research findings are freely available to the global scientific community, thereby enhancing the visibility and impact of published work. With a commitment to fostering collaboration and disseminating high-quality research, Life Science Alliance serves as an essential platform for the promotion and exchange of scientific knowledge, aiming to bridge gaps and stimulate discussions across multiple disciplines.

JOURNAL OF GENE MEDICINE

Elevating Standards in Gene Medicine Research
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Blood Cancer Discovery

Pioneering Discoveries for a Cancer-Free Tomorrow
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

CELLULAR & MOLECULAR BIOLOGY LETTERS

Advancing the Frontiers of Cellular and Molecular Science
Publisher: BMCISSN: 1425-8153Frequency: 1 issue/year

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

Therapeutic Advances in Hematology

Advancing hematology through innovative research.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

BONE MARROW TRANSPLANTATION

Elevating Standards in Hematology and Transplantation.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

Journal of Hematology & Oncology

Advancing the Frontiers of Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Molecular Oncology

Transforming Cancer Insights into Global Knowledge.
Publisher: WILEYISSN: 1574-7891Frequency: 10 issues/year

Molecular Oncology, published by WILEY, is a premier open-access journal that has been at the forefront of cancer research since its inception in 2007. With an impressive impact factor reflective of its outstanding contribution to the field, it holds a prestigious position in the Q1 category across multiple disciplines, including Cancer Research, Genetics, and Molecular Medicine. This journal is essential for researchers and professionals seeking to publish high-quality findings in a rapidly evolving area of study, underscored by its significant Scopus rankings that place it within the top percentiles of Oncology and Molecular Biology. As an open-access journal since 2017, it ensures that vital research is readily available to a global audience, thereby facilitating collaboration and knowledge dissemination among academic and clinical communities. With its commitment to innovative and impactful research, Molecular Oncology continues to be a critical resource for advancing our understanding of cancer biology and treatment.